Cargando…

Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?

High inter-patient variability and high spatial heterogeneity are features of colorectal cancer (CRC). This may influence the molecular characterization of tumor tissue, now mandatory for patients with metastatic CRC who are candidates for treatment with an anti-EGFR mAb, as false-negative results c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molinari, Chiara, Marisi, Giorgia, Passardi, Alessandro, Matteucci, Laura, De Maio, Giulia, Ulivi, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321493/ https://www.ncbi.nlm.nih.gov/pubmed/30477151 http://dx.doi.org/10.3390/ijms19123733

Ejemplares similares

Metastatic Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2021)

Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
por: Ulivi, Paola, et al.
Publicado: (2016)

Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients
por: Pirini, Francesca, et al.
Publicado: (2020)

Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
por: Ulivi, Paola, et al.
Publicado: (2021)

Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer
por: Marisi, Giorgia, et al.
Publicado: (2023)

Discrepancies between VEGF −1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue
por: Marisi, Giorgia, et al.
Publicado: (2014)

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2018)

Molecular and Translational Research on Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2020)

Special Issue on Basic and Translational Research in Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

Special Issue on Molecular and Translational Research on Colorectal Cancer 2.0
por: Passardi, Alessandro, et al.
Publicado: (2021)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018)

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017)

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017)

Immune Checkpoints as a Target for Colorectal Cancer Treatment
por: Passardi, Alessandro, et al.
Publicado: (2017)

Towards Personalized Treatment and Molecular Research on Gastrointestinal Tumors
por: Passardi, Alessandro, et al.
Publicado: (2023)

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial
por: Ulivi, Paola, et al.
Publicado: (2015)

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
por: Matteucci, Laura, et al.
Publicado: (2023)

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab
por: Del Re, Marzia, et al.
Publicado: (2014)

Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

Editorial: Identification of novel biomarkers for pancreatic and hepatocellular cancers
por: Matteucci, Laura, et al.
Publicado: (2022)

Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Editorial: MicroRNAs as biomarkers in colorectal cancer
por: Ulivi, Paola
Publicado: (2023)

Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial
por: Casadei Gardini, Andrea, et al.
Publicado: (2020)

Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2015)

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
por: Ulivi, Paola, et al.
Publicado: (2012)

Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy
por: Rosati, Gerardo, et al.
Publicado: (2022)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Personalized medicine in colorectal cancer
por: Vaseghi Maghvan, Padina, et al.
Publicado: (2020)

Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis
por: Mori, Giorgia, et al.
Publicado: (2018)

Genetic Predisposition to Colorectal Cancer: How Many and Which Genes to Test?
por: Rebuzzi, Francesca, et al.
Publicado: (2023)

Genetic heterogeneity in breast cancer: the road to personalized medicine?
por: Baird, Richard D, et al.
Publicado: (2013)

Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models
por: Tesei, Anna, et al.
Publicado: (2011)

(1)H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages
por: Casadei-Gardini, Andrea, et al.
Publicado: (2020)

The challenges and hopes of personalized cancer medicine
por: Xian, Wa, et al.
Publicado: (2011)

Recent Research on Gastrointestinal Carcinoma
por: Rovesti, Giulia, et al.
Publicado: (2021)

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

Colorectal Cancer Biomarkers in the Era of Personalized Medicine
por: Patel, Jai N., et al.
Publicado: (2019)

Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival
por: Gardini, Andrea Casadei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lnfsj3igtutfoq9gi2u94afdc5